Oncotarget

Research Papers:

IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T. Keller, Jian Zhang, Yi Lu _

PDF |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:68140-68150. https://doi.org/10.18632/oncotarget.11886

Metrics: PDF 900 views  |   HTML 565 views  |   ?  


Abstract

Qiuyan Chen1,2,*, Siyuan Qin3,4,*, Yang Liu3,4, Minghuang Hong1,2, Chao-Nan Qian1,2, Evan T. Keller5, Jian Zhang3,4,6, Yi Lu3,4,6

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

3Key Laboratory of Longevity and Aging-related Diseases, Ministry of Education, Guangxi Medical University, Nanning, Guangxi, China

4Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, China

5Department of Urology and Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA

6Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

*These authors contributed equally to this work

Correspondence to:

Yi Lu, email: luyi5555@hotmail.com

Keywords: IGFBP6, GSK3β, β-catenin, cyclin D1, nasopharyngeal carcinoma

Received: June 11, 2016     Accepted: September 01, 2016     Published: September 07, 2016

ABSTRACT

Insulin-like growth factor binding proteins (IGFBPs) play critical roles in carcinogenesis. This study assessed the impact of IGFBP6 on the progression of nasopharyngeal carcinoma (NPC). Using immunohistochemical analysis, we found that IGFBP6 was differentially expressed in primary malignant NPC tissues. Clinical samples were divided into two groups: IGFBP6(+) and IGFBP6(−). Five years of follow-up revealed that overall survival and distant metastasis-free survival rates were significantly higher in the IGFBP6(+) than IGFBP6(−) group. We also used real-time PCR, ELISA and western blot assays to measure IGFBP6 levels in five NPC cell lines (CNE1, CNE2, HONE1, HK1 and SUNE1). All the cell lines expressed IGFBP6, but at different levels, reflecting disease heterogeneity. In addition, exogenous expression of IGFBP6 inhibited CNE2 cell proliferation and invasion in vitro. IGFBP6 knockdown activated the GSK3β/β-catenin/cyclin D1 pathway and enhanced CNE2 tumor cell growth and metastasis in a mouse model. These results suggest that IGFBP6 may be an independent prognostic biomarker for NPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11886